Three months of weekly rifapentine plus isoniazid for TB prevention among people with HIV.

IJTLD open Pub Date : 2024-09-01 DOI:10.5588/ijtldopen.23.0609

R Borse, B Randive, S Mattoo, P Malik, H Solanki, A Gupta, R E Chaisson, V Mave, N Suryavanshi

{"title":"Three months of weekly rifapentine plus isoniazid for TB prevention among people with HIV.","authors":"R Borse, B Randive, S Mattoo, P Malik, H Solanki, A Gupta, R E Chaisson, V Mave, N Suryavanshi","doi":"10.5588/ijtldopen.23.0609","DOIUrl":null,"url":null,"abstract":"Background: Evidence on implementation of three months of weekly isoniazid (H, INH) and rifapentine (P, RPT) (3HP) as a TB preventive therapy (TPT) for at-risk groups in Indian programmatic conditions is limited.Methods: A prospective demonstration study assessing scale-up, safety, and effectiveness of 3HP TPT among people living with HIV (PLHIV) in Indian programmatic settings was conducted.Results: Of 656 screened PLHIV, 502 (77%) received 3HP. Of these, 20 (4%) discontinued TPT due to toxicity,17 (3.8%) lost to follow-up, one (0.2%) had breakthrough rifampicin-sensitive TB, and 464 (92%) completed 3 HP TPT. Of 288 (57%) overall adverse events (AEs), 46 (9%) had Grade 2 or above AEs. The median time to AE was 14 days (IQR 7-42). Serious adverse events (SAEs) were reported in 9 (2%) participants; of these, 7 (78%) were not related to 3HP. No TB episodes occurred during the 1-year follow-up period.Conclusion: 3HP TPT completion rate of 92%, with few adverse events leading to 3HP discontinuation, providing evidence of the scalability and safety of 3HP TPT among PLHIV in Indian health program settings.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"1 9","pages":"404-409"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11409171/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJTLD open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5588/ijtldopen.23.0609","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Evidence on implementation of three months of weekly isoniazid (H, INH) and rifapentine (P, RPT) (3HP) as a TB preventive therapy (TPT) for at-risk groups in Indian programmatic conditions is limited.

Methods: A prospective demonstration study assessing scale-up, safety, and effectiveness of 3HP TPT among people living with HIV (PLHIV) in Indian programmatic settings was conducted.

Results: Of 656 screened PLHIV, 502 (77%) received 3HP. Of these, 20 (4%) discontinued TPT due to toxicity,17 (3.8%) lost to follow-up, one (0.2%) had breakthrough rifampicin-sensitive TB, and 464 (92%) completed 3 HP TPT. Of 288 (57%) overall adverse events (AEs), 46 (9%) had Grade 2 or above AEs. The median time to AE was 14 days (IQR 7-42). Serious adverse events (SAEs) were reported in 9 (2%) participants; of these, 7 (78%) were not related to 3HP. No TB episodes occurred during the 1-year follow-up period.

Conclusion: 3HP TPT completion rate of 92%, with few adverse events leading to 3HP discontinuation, providing evidence of the scalability and safety of 3HP TPT among PLHIV in Indian health program settings.

查看原文本刊更多论文

为预防艾滋病病毒感染者感染结核病，每周服用利福喷丁加异烟肼三个月。

背景：在印度计划条件下，对高危人群实施为期三个月的每周异烟肼（H，INH）和利福喷汀（P，RPT）（3HP）结核病预防疗法（TPT）的证据有限：方法：开展了一项前瞻性示范研究，评估 3HP TPT 在印度计划环境中艾滋病毒感染者（PLHIV）中的推广、安全性和有效性：在 656 名经过筛查的艾滋病毒感染者中，502 人（77%）接受了 3HP 治疗。其中，20 人（4%）因毒性中止了 TPT，17 人（3.8%）失去了随访，1 人（0.2%）出现了突破性利福平敏感结核病，464 人（92%）完成了 3HP TPT。在288例（57%）总体不良事件（AEs）中，46例（9%）为2级或2级以上不良事件。发生 AE 的中位时间为 14 天（IQR 7-42）。9名参与者（2%）报告了严重不良事件（SAE），其中7名（78%）与3HP无关。结论：3HP TPT 的完成率为 92%，导致停用 3HP 的不良事件很少，证明了 3HP TPT 在印度卫生项目环境中的 PLHIV 中的可扩展性和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

IJTLD open

自引率

0.00%

发文量